Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2020

Product sales, net

Schedule of Disaggregation of Revenues

During the years ended December 31, 2020, 2019 and 2018, the Company recorded product sales, net, as follows:

	Year Ended December 31,
(In thousands)	2020		2019		2018
VIVITROL	$	310,722	$	335,365	$	302,609
ARISTADA and ARISTADA INITIO		241,038		189,134		147,725
Total product sales, net	$	551,760	$	524,499	$	450,334

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the years ended December 31, 2020, 2019 and 2018, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

	Year Ended December 31, 2020
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	$	—	$	274,200	$	274,200
RISPERDAL CONSTA		56,893		14,468		71,361
AMPYRA/FAMPYRA		26,909		20,984		47,893
Other		35,232		55,314		90,546
	$	119,034	$	364,966	$	484,000

	Year Ended December 31, 2019
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	$	—	$	256,947	$	256,947
RISPERDAL CONSTA		50,433		15,950		66,383
AMPYRA/FAMPYRA		22,071		15,170		37,241
Other		31,750		55,561		87,311
	$	104,254	$	343,628	$	447,882

	Year Ended December 31, 2018
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	$	—	$	241,423	$	241,423
RISPERDAL CONSTA		52,770		18,352		71,122
AMPYRA/FAMPYRA		53,044		54,009		107,053
Other		27,214		79,863		107,077
	$	133,028	$	393,647	$	526,675